Argentina

The Administración Nacional de Medicamentos, Alimentos y Tecnología Médica (ANMAT) is the primary national regulatory authority in Argentina, established under Decree 1490/1992 and operating under the purview of the Ministerio de Salud de la Nación. ANMAT oversees the registration, authorization, surveillance, and control of pharmaceuticals, medical devices, in vitro diagnostics, and digital health technologies marketed in Argentina. The general approval process requires submission of a formal dossier through ANMAT's electronic platform (SISTRATA for devices or the corresponding pharmaceutical module), followed by technical and administrative review, potential requests for additional information, and issuance of a Certificate of Authorization (Certificado de Autorización) or product registration number (Certificado de Inscripción en el RPPTM for devices). Risk-based classification determines the depth of review, with higher-risk products subject to more rigorous evaluation.

All applicants must appoint a locally registered technical director or legal representative domiciled in Argentina, who assumes regulatory and legal responsibility for the product. Argentina generally accepts dossiers structured according to the Common Technical Document (CTD) format for pharmaceuticals, and aligns medical device submissions with IMDRF guidance frameworks, reflecting its participation in the Pan American Network for Drug Regulatory Harmonization (PANDRH) and engagement with IMDRF processes. ANMAT Disposition 2318/2002 and subsequent updates govern medical device registration, while Disposition 7075/2011 and related norms address in vitro diagnostics. Notable recent reforms include the progressive digitalization of submission and tracking processes, streamlined pathways for products previously approved by reference regulatory authorities (such as FDA, EMA, Health Canada, and ANVISA), and updated guidance on software as a medical device (SaMD) and digital health tools, reflecting growing regulatory attention to health technology convergence.

Public procurement of health products in Argentina operates through a multi-layered federal structure. At the national level, the Ministerio de Salud de la Nación coordinates centralized purchasing programs through entities such as the Unidad de Coordinación General de Gestión de Recursos Humanos y Administración and procurement arms linked to national health programs, including the Programa Remediar for essential medicines and the national immunization program (Calendario Nacional de Vacunación) managed by the Dirección Nacional de Control de Enfermedades Inmunoprevenibles. Large-scale centralized tenders are conducted through the Oficina Nacional de Contrataciones (ONC) under the Sistema de Contrataciones Electrónicas Argentina (COMPR.AR), which mandates transparent competitive bidding. Individual provincial health ministries and hospital networks retain significant autonomous procurement authority under Argentina's federal structure, meaning suppliers must often engage at both national and provincial levels. Public hospitals and provincial health secretariats issue their own tender processes, creating a fragmented but substantial public market that requires localized commercial and registration strategies.

The private sector constitutes a significant share of health product consumption in Argentina, channeled through pharmaceutical distributors, hospital groups, private clinics, pre-paid health plans (obras sociales and empresas de medicina prepaga), and retail pharmacy chains. The obras sociales system, regulated by the Superintendencia de Servicios de Salud, mandates coverage of certain product categories and influences formulary inclusion decisions. International donor and multilateral procurement channels play a more limited role in Argentina compared to lower-income regional markets; however, agencies such as PAHO/WHO, UNICEF, and the Global Fund have historically supported specific disease programs including HIV/AIDS and tuberculosis procurement. Argentina maintains policies favoring domestic pharmaceutical and medical device manufacturing through preferential margin schemes for locally produced goods in public tenders, governed by regulations that award price preference to products manufactured within the country, incentivizing local production partnerships and in-country manufacturing investments as a market access strategy.